Tech Company Financing Transactions
Orikine Bio Funding Round
Orikine Bio secured a $840 thousand financing round on 12/3/2024. Investors included private investors.
Transaction Overview
Company Name
Announced On
12/3/2024
Transaction Type
Venture Equity
Amount
$840,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intend sto use the funds to advance preclinical proof-of-concept for FoldikineTM ORK-1, its drug candidate for autoimmune/inflammatory diseases.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
C/ del Dr. Aiguader, 88
Barcelona, 08003
Spain
Barcelona, 08003
Spain
Phone
Website
Email Address
Overview
Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alejo Chorny
Founder
Javier Delgado
Founder
Ariadna Montero
Founder
Luis Pubul
Browse more venture capital transactions:
Prev: 12/3/2024: DPL Financial Partners venture capital transaction
Next: 12/3/2024: Aerospike venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs